13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001697013
Total reported value
$1.9B
$1.9B
107 檔
33.0%
The Q4 2025 SEC filing reveals that Eversept Partners, LP held a total portfolio value of $1.9B, covering 107 public equity positions.
In Q4 2025, Eversept Partners, LP displayed an active expansion posture, initiating 38 new positions and adding to 37 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including VERA, QQQ, GSK) accounted for 33.0% of total reported equity market value during Q4 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VERA | Vera Therapeutics Inc | Stock-Other | 7.84% | +0.32% | +9.42% | |
| 2 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 6.97% | -3.49% | -2.17% | |
| 3 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 6.62% | -3.89% | +26.38% | |
| 4 | UTHR | United Therapeutics CORP | Stock-Healthcare | 6.20% | -0.17% | -6.25% | |
| 5 | ABVX | Abivax Sa-adr | Stock-Other | 4.47% | +0.83% | +54.24% | |
| 6 | NTRA | Natera Inc | Stock-Healthcare | 3.86% | -1.58% | -35.63% | |
| 7 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.51% | -0.38% | -4.41% | |
| 8 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.79% | +0.05% | -7.38% | |
| 9 | PCVX | Vaxcyte Inc | Stock-Other | 2.78% | -0.93% | -15.77% | |
| 10 | TVTX | Travere Therapeutics Inc | Stock-Other | 2.26% | +1.50% | -17.09% | |
| 11 | HCA | Hca Healthcare Inc | Stock-Healthcare | 2.26% | +0.01% | -14.17% | |
| 12 | DHR | Danaher CORP | Stock-Healthcare | 2.15% | — | +87.63% | |
| 13 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.15% | +0.23% | -0.08% | |
| 14 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.96% | +0.46% | +24.33% | |
| 15 | BRKR | Bruker CORP | Stock-Healthcare | 1.86% | +0.35% | +14.07% | |
| 16 | AVTR | Avantor Inc | Stock-Healthcare | 1.83% | -1.23% | EXIT | |
| 17 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 1.54% | -3.67% | EXIT | |
| 18 | CYH | Community Health Systems Inc | Stock-Other | 1.25% | +0.01% | +14.30% | |
| 19 | EXK | Exact Sciences CORP | Stock-Materials | 1.24% | — | — | |
| 20 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.18% | -0.56% | +117.88% | |
| 21 | GERN | Geron CORP | Stock-Other | 1.17% | -0.24% | +40.17% | |
| 22 | TECH | Bio-techne CORP | Stock-Healthcare | 1.12% | -0.28% | -36.20% | |
| 23 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.10% | — | — | |
| 24 | PODD | Insulet CORP | Stock-Healthcare | 1.07% | -0.41% | +63.82% | |
| 25 | BBNX | Beta Bionics Inc | Stock-Other | 1.04% | +0.27% | — | |
| 26 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 1.04% | — | -51.59% | |
| 27 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.01% | +0.53% | -3.12% | |
| 28 | TLT | Ishares 20+ Year Treasury Bd | ETF-Gov Bonds | 1.01% | -1.96% | EXIT | |
| 29 | LQDA | Liquidia CORP | Stock-Other | 0.89% | +0.42% | +4.82% | |
| 30 | ICLR | ICON Public Limited Company | Stock-Healthcare | 0.88% | -0.40% | EXIT | |
| 31 | HQY | Healthequity Inc | Stock-Healthcare | 0.86% | -0.23% | EXIT | |
| 32 | GKOS | Glaukos CORP | Stock-Healthcare | 0.84% | -0.13% | — | |
| 33 | RVTY | Revvity Inc | Stock-Healthcare | 0.79% | +0.09% | -58.72% | |
| 34 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.74% | — | -13.87% | |
| 35 | ESPR | Esperion Therapeutics Inc | Stock-Other | 0.72% | -0.25% | EXIT | |
| 36 | BIIB | Biogen Inc | Stock-Healthcare | 0.69% | — | +50.57% | |
| 37 | SEM | Select Medical Holdings CORP | Stock-Other | 0.68% | — | — | |
| 38 | CNC | Centene CORP | Stock-Healthcare | 0.67% | -0.19% | EXIT | |
| 39 | CGON | Cg Oncology Inc | Stock-Other | 0.65% | — | — | |
| 40 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 0.64% | — | — | |
| 41 | PALI | Palisade Bio Inc | Stock-Other | 0.64% | -0.01% | — | |
| 42 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.64% | -0.54% | +289.93% | |
| 43 | PHVS | Pharvaris N.V. | Stock-Other | 0.61% | +0.08% | — | |
| 44 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 0.61% | +0.05% | — | |
| 45 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.58% | +0.33% | — | |
| 46 | EHC | Encompass Health CORP | Stock-Healthcare | 0.57% | +4.39% | — | |
| 47 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.54% | -0.10% | — | |
| 48 | ELV | Elevance Health Inc | Stock-Healthcare | 0.53% | — | -32.87% | |
| 49 | MNKD | Mannkind CORP | Stock-Other | 0.53% | — | -9.31% | |
| 50 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.52% | +0.22% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VERA | Vera Therapeutics Inc | +2.2% | +9.42% | Add |
| 2 | ABVX | Abivax Sa-adr | +2% | +54.24% | Add |
| 3 | AVTR | Avantor Inc | +1% | +243.63% | Add |
| 4 | DHR | Danaher CORP | +0.8% | +87.63% | Add |
| 5 | HQY | Healthequity Inc | +0.5% | +254.54% | Add |
| 6 | ARQT | Arcutis Biotherapeutics Inc | +0.5% | +289.93% | Add |
| 7 | BCRX | Biocryst Pharmaceuticals Inc | +0.5% | +117.88% | Add |
| 8 | PNTG | Pennant Group Inc/the | +0.4% | +673.99% | Add |
| 9 | BRKR | Bruker CORP | +0.3% | +14.07% | Add |
| 10 | GSK | Gsk Plc-spon Adr | +0.3% | +26.38% | Add |
| 11 | MOH | Molina Healthcare Inc | +0.3% | +380.15% | Add |
| 12 | ICLR | ICON Public Limited Company | +0.2% | +74.16% | Add |
| 13 | BIIB | Biogen Inc | +0.2% | +50.57% | Add |
| 14 | LQDA | Liquidia CORP | +0.1% | +4.82% | Add |
| 15 | GPCR | Structure Therapeutics Inc | +0.1% | -23.34% | Trim |
| 16 | CNC | Centene CORP | +0.1% | +44.33% | Add |
| 17 | HUM | Humana Inc | +0.1% | +94.94% | Add |
| 18 | TYRA | Tyra Biosciences Inc | +0.1% | +2.15% | Add |
| 19 | IVVD | Invivyd Inc | +0.1% | +4.54% | Add |
| 20 | PODD | Insulet CORP | +0.1% | +63.82% | Add |
| 21 | ISRG | Intuitive Surgical Inc | +0.1% | +25.20% | Add |
| 22 | FTRE | Fortrea Holdings Inc | +0.1% | +2.17% | Add |
| 23 | MRVI | Maravai Lifesciences Hldgs-a | +0.1% | +147.21% | Add |
| 24 | RLAY | Relay Therapeutics Inc | 0% | +2.10% | Add |
| 25 | SRZN | Surrozen Inc | 0% | +23.75% | Add |
| 26 | EHTH | Ehealth Inc | 0% | +73.45% | Add |
| 27 | CBLL | Ceribell Inc | 0% | — | Unchanged |
| 28 | DVAX | Dynavax Technologies CORP | — | -12.62% | Trim |
| 29 | ACAD | Acadia Pharmaceuticals Inc | — | +7.52% | Add |
| 30 | RVP | Retractable Technologies Inc | — | +59.89% | Add |
| 31 | GERN | Geron CORP | 0% | +40.17% | Add |
| 32 | ZBIO | Zenas Biopharma Inc | 0% | -23.77% | Trim |
| 33 | BVS | Bioventus Inc - A | 0% | +8.60% | Add |
| 34 | AVR | Anteris Technologies Global | 0% | — | Unchanged |
| 35 | PLRX | Pliant Therapeutics Inc | 0% | +2.11% | Add |
| 36 | CTNM | Contineum Therapeutics Inc-a | 0% | +2.13% | Add |
| 37 | ARDX | Ardelyx Inc | 0% | +19.99% | Add |
| 38 | BCYC | Bicycle Therapeutics Plc-adr | 0% | -7.98% | Trim |
| 39 | CPRX | Catalyst Pharmaceuticals Inc | -0.1% | +2.10% | Add |
| 40 | VRDN | Viridian Therapeutics Inc | -0.1% | -7.38% | Trim |
| 41 | TVTX | Travere Therapeutics Inc | -0.1% | -17.09% | Trim |
| 42 | IFRX | InflaRx N.V. | -0.1% | +1.54% | Add |
| 43 | AMRN | Amarin CORP PLC -adr | -0.1% | +2.94% | Add |
| 44 | NVAX | Novavax Inc | -0.1% | -25.48% | Trim |
| 45 | CLDX | Celldex Therapeutics Inc | -0.1% | +24.33% | Add |
| 46 | EWTX | Edgewise Therapeutics Inc | -0.1% | -32.83% | Trim |
| 47 | SNDX | Syndax Pharmaceuticals Inc | -0.2% | -4.41% | Trim |
| 48 | RAPP | Rapport Therapeutics Inc | -0.2% | -58.74% | Trim |
| 49 | ALEC | Alector Inc | -0.2% | -32.41% | Trim |
| 50 | NAMS | NewAmsterdam Pharma Company N.V. | -0.2% | -13.87% | Trim |
According to official SEC Form 13F filings, Eversept Partners, LP reported a total U.S. public equity portfolio value of $1.9B across 107 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
SPY
市值: $30.6M
Top Position Liquidated / Trimmed
ZIMV
前期市值: $39.4M
During Q4 2025, Eversept Partners, LP's top holdings by market value included VERA (7.8%)、QQQ (7.0%)、GSK (6.6%). The largest single position, VERA, represented 7.8% of total portfolio value.
In Q4 2025, Eversept Partners, LP made 121 total portfolio adjustments, initiating 38 new buys, adding to 37 positions, trimming 30 holdings, and fully liquidating 16 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.